FILING ANALYSIS · MONDAY, NOVEMBER 16

20/20 Biolabs, Inc. AIDX — 8-K: Results of Operations and Financial Condition

positive

20/20 BioLabs reported a 4.1% increase in OneTest revenue to $1.36 million for the first nine months of 2026, with a gross margin expansion to 32.8%, and announced a two-year contract with Vermont for firefighter cancer screening, expected to contribute revenue in Q4 2026. The company has $3.63 million in cash and no outstanding debt as of September 30, 2026.

The filing

8-K - 20/20 Biolabs, Inc. (0001139685) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+